<DOC>
	<DOCNO>NCT00122694</DOCNO>
	<brief_summary>The purpose study determine whether carbon monoxide effective treatment stable COPD .</brief_summary>
	<brief_title>Modification Chronic Inflammation Inhaled Carbon Monoxide Patients With Stable Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description>COPD characterise chronic pulmonary inflammation shift oxidant/antioxidant balance . The main cause inflammation smoking . After smoke cessation , inflammation shift oxidant/antioxidant balance continue . This cause increased deterioration lung function compare healthy person match age . The ongoing inflammation appear relatively insensitive corticosteroid therapy . Until , therapy inflammation . Both vitro vivo study show carbon monoxide , besides antioxidant capacity , anti-inflammatory property . The aim trial study whether inflammation reduce inhalation carbon monoxide .</detailed_description>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Carbon Monoxide</mesh_term>
	<criteria>Men woman , age &gt; 40 year . Women must postmenopausal ( i.e . least one year must pass last menstruation ) , surgically sterile use acceptable contraceptive , judge investigator . A diagnosis COPD accord criterion American Thoracic Society ( ATS ) ; disease state characterise presence chronic airway obstruction due chronic bronchitis ( cough/sputum day week 3 month year least two successive year ) ; emphysema . FEV1 &gt; 0.7 litre FEV1/FVC ratio &lt; 70 % ( equation retrieval system [ ERS ] equation ) A smoke history &gt; 10 pack year Completely stop smoke &gt; 1 year ago No upper low respiratory tract infection last 4 week In stable phase COPD , judge investigator Signed date informed consent obtain study related procedure ( include withdrawal concomitant medication ) conduct Treatment immunemodulating agent disease History asthma ; former diagnosis asthma Arterial oxygen tension ( PaO2 ) &lt; 8.0 kPa Any significant pulmonary disease disorder ( e.g . alpha1antitrypsin deficiency , bronchiectasies ) , judge investigator Patients significant disease disorder ( like cardiovascular , gastrointestinal , liver , renal , neurological , musculoskeletal , endocrine , metabolic [ include diagnose diabetes ] , malignant , psychiatric , major physical impairment ) , , opinion investigator may either put patient risk participation study ; may influence result study , patient â€™ ability participate study . Patients unable blow reproducable lung function measurement Patients use medicine antioxidant character like nacetylcysteine .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2006</verification_date>
	<keyword>carbon monoxide</keyword>
	<keyword>COPD</keyword>
	<keyword>inflammation</keyword>
	<keyword>sputum induction</keyword>
	<keyword>stable COPD</keyword>
</DOC>